Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 58Neoplasms 51Colorectal Neoplasms 32Prostatic Neoplasms 29Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 23Leukemia, Myeloid, Acute 20Recurrence 12Multiple Myeloma 12Head and Neck Neoplasms 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Neoplasm Metastasis 11Melanoma 11Squamous Cell Carcinoma of Head and Neck 10Lymphoma, Non-Hodgkin 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Myelodysplastic Syndromes 8Motor Activity 8Lymphoma 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8Leukemia 7Glioblastoma 7Polycystic Ovary Syndrome 6

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castrate Sensitive Prostate Cancer × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡